India's First Homegrown FDA Drug | Is Airtel's Fast Lane Fair? | Godrej Enters Wealth
About this episode
The episode covers India's first homegrown FDA drug approval, Godrej's new wealth management arm, and various economic challenges faced by startups.
Good Morning, I'm Nelson John. Today on Top of the Morning: Godrej launches its wealth arm with a ₹1 lakh crore target. Wockhardt wins FDA approval for India's first fully homegrown new drug. The weak rupee is squeezing AI startups, and founders are getting creative. The regulator looks set to clear Airtel's priority 5G plan. And the Supreme Court closes the casino industry's tax loophole. Five stories, ten minutes, no fluff. Listen now. Learn more about your ad choices. Visit megaphone.fm/adchoices
More episodes of Top of the Morning
- India's Tax Free Dollar Deposit That Pays Like Equity | Central Banks Turn Hawkish, And India Watches
- India's Hunt For World Class Universities | Modi, The States, And The Jobs Question | TCS & The Million Agent Prediction
- Full Rooms, Falling Stocks | Big Money Eyes Indian Roads and Grids | More Milk, Even With a Dry Sky
- India Hit With New Tariffs | ₹15 Trillion Fraud? | The Deal That's 99% Done
- Why Foreign Money Skips India | Adani's Hidden Builder | Mythos Too Dangerous to Release |
- Your Salary, On Auto-Invest | Made In India, Sold Abroad | GIFT City Goes After Global Money
Explore listener stats, chart rankings, contacts and more on the Top of the Morning podcast page.